Article Text

Download PDFPDF

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
  1. Helen A Dakin1,
  2. Sarah Wordsworth1,
  3. Chris A Rogers2,
  4. Giselle Abangma3,
  5. James Raftery4,
  6. Simon P Harding5,
  7. Andrew J Lotery6,
  8. Susan M Downes7,
  9. Usha Chakravarthy8,
  10. Barnaby C Reeves2,
  11. on behalf of the IVAN Study Investigators
  1. 1Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK
  2. 2Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
  3. 3Swiss Re Services Ltd, Research and Development, London, UK
  4. 4Primary Care & Population Sciences, University of Southampton, Southampton, UK
  5. 5Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK
  6. 6Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
  7. 7Oxford Eye Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
  8. 8Centre for Experimental Medicine, The Queen's University of Belfast, Belfast, UK
  1. Correspondence to Helen A Dakin; helen.dakin{at}

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.